The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 24, 2017
Filed:
Jul. 12, 2010
Hisashi Narimatsu, Ibaraki, JP;
Jun Hirabayashi, Ibaraki, JP;
Yuzuru Ikehara, Ibaraki, JP;
Takashi Angata, Ibaraki, JP;
Hiroyuki Kaji, Ibaraki, JP;
Atsushi Kuno, Ibaraki, JP;
Takashi Ohkura, Ibaraki, JP;
Toshihide Shikanai, Ibaraki, JP;
Maki Sogabe, Ibaraki, JP;
Akira Togayachi, Ibaraki, JP;
Makoto Ochou, Ibaraki, JP;
Yasuhito Tanaka, Aichi, JP;
Masashi Mizokami, Chiba, JP;
Hisashi Narimatsu, Ibaraki, JP;
Jun Hirabayashi, Ibaraki, JP;
Yuzuru Ikehara, Ibaraki, JP;
Takashi Angata, Ibaraki, JP;
Hiroyuki Kaji, Ibaraki, JP;
Atsushi Kuno, Ibaraki, JP;
Takashi Ohkura, Ibaraki, JP;
Toshihide Shikanai, Ibaraki, JP;
Maki Sogabe, Ibaraki, JP;
Akira Togayachi, Ibaraki, JP;
Makoto Ochou, Ibaraki, JP;
Yasuhito Tanaka, Aichi, JP;
Masashi Mizokami, Chiba, JP;
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, Tokyo, JP;
PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY, Aichi, JP;
NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE, Tokyo, JP;
GLYCOBIOMARKER LEADING INNOVATION CO., LTD., Ibaraki, JP;
Abstract
The present invention is directed to developing a glycan markers capable of detecting a hepatic disease, and more specifically to developing a glycan marker indicating a hepatic disease-state. Furthermore, the present invention is also directed to developing a glycan marker capable of distinguishing hepatic disease-states with the progress of hepatocarcinoma. The present inventors identified, among the serum glycoproteins, glycopeptides and glycoproteins in which a glycan structure specifically changes due to a hepatic diseases including hepatocarcinoma and provide these as novel glycan markers (glycopeptide and glycoprotein) specific to hepatic disease-states.